Financials data is unavailable for this security.
View more
Year on year Catalyst Pharmaceuticals Inc had net income fall -14.05% from 83.08m to 71.41m despite a 85.90% increase in revenues from 214.20m to 398.20m. An increase in the selling, general and administrative costs as a percentage of sales from 27.16% to 33.58% was a component in the falling net income despite rising revenues.
| Gross margin | 86.32% |
|---|---|
| Net profit margin | 31.01% |
| Operating margin | 37.78% |
| Return on assets | 24.10% |
|---|---|
| Return on equity | 28.29% |
| Return on investment | 27.94% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Catalyst Pharmaceuticals Inc fell by 160.76m. However, the company earned 143.60m from its operations for a Cash Flow Margin of 36.06%. In addition the company used 293.50m on investing activities and also paid 10.86m in financing cash flows.
| Cash flow per share | 1.48 |
|---|---|
| Price/Cash flow per share | 13.97 |
| Book value per share | 5.54 |
|---|---|
| Tangible book value per share | 4.15 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.11 |
|---|---|
| Quick ratio | 4.92 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -15.84%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 123.05 |
